EQ-3
2.8.2016 10:02:00 CEST | Business Wire | Press release
According to the renowned market research company Berg Insight, eQ-3 is the European market leader in smart home for the third time in a row. The company jumps ahead with a market share of 35 percent in installed whole home solutions: About 285,000 households in Europe already use whole home solutions from eQ-3. With regard to smart thermostats, there are over 560,000 households already. In total eQ-3 has shipped more than 18 million wireless home control devices.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005208/en/
The market research company Berg Insight confirms the company located in Leer, Germany, as market leader in its fourth edition of the “Smart Homes and Home Automation” study. Whole home systems by eQ-3 are already installed in around 285,000 households in Europe today. These include more than six million devices based on the Homematic product line as well as the next smart home generation Homematic IP and major OEM solutions such as RWE smart home. The company has recorded continuous growth over many years in the smart home area, largely thanks to the product line Homematic introduced almost ten years ago. In the last three years, Homematic growth exceeded 75 percent per year, even with the already large installed base. According to Berg Insight, Homematic has three times more installed whole home systems in the consumer segment than all KNX manufacturers together.
The same positive trend becomes apparent when looking at the smart thermostats sector: Over 560,000 households in Europe use smart thermostats from eQ-3 already today, representing a market share of 41 percent. According to Berg Insight, the heating control system MAX! is used in 320,000 households.
In contrast to other smart thermostat solutions, eQ-3 solutions such as Homematic IP, Homematic, and MAX! provide heating control not only for the entire home, but on a room-by-room basis. Therefore, the energy is controlled based on the actual usage of rooms and associated need for heating rooms individually. This results in significantly increased energy savings. Furthermore, while other solutions typically consist of a boiler switch, a thermostat, and a gateway only, the eQ-3 solutions additionally include radiator thermostats, wall thermostats, and window sensors and other devices. When considering that a typical eQ-3 heating solution has eight to nine versus two to three devices, the European market share of eQ-3 based on the number of individual devices would be even above 70 percent.
Another major difference to other smart heating solutions is that eQ-3 provides a smooth extension path to full smart home solutions today, seamlessly adding security and alarm, light and shade, access control and many other applications for mass consumer deployment. The eQ-3 smart home products are marketed under the Homematic IP, Homematic, and MAX! brands through a wide variety of channels, including specialty retailers, Amazon and many online stores, large CE retailers, DIY, and installers that are served by our own field sales force together with the leading electrical wholesaler Sonepar. Additionally, eQ-3 is the technology and product provider behind smart home offerings from RWE, Deutsche Telekom and many other OEMs. With Homematic IP and an earlier OEM solution, eQ-3 is the pioneer in delivering an all-IPv6 smart home solution. Further strengths of Homematic IP are its ease-of-use, confirmed best-in-class security, and a leading position in data privacy thanks to a free, anonymously operated cloud service.
Homematic IP by eQ-3
About eQ-3:
eQ-3 is one of the leading innovation and technology companies for home control and consumer electronics. With more than 200 different types of products, eQ-3 today provides the largest product portfolio in the industry and has placed more than 18 million wireless solutions in more than 600,000 households on the market. This makes eQ-3 the European market leader in smart home technology based on the number of whole home solutions and electronic radiator thermostats installed. Homematic is the leading smart home platform with more than 80 devices and open communication interfaces. Homematic IP, the next generation of Homematic, is based on the Internet standard IPv6 as open platform and fully compatible with the devices of the Homematic family. The products are designed and developed at the headquarters in Leer, Germany. The final manufacturing takes place in the own production plant in South China. The ELV/eQ-3 group has been family owned since its foundation. The eQ-3 group was founded in 2007 as a spin-off from the ELV Elektronik AG, existing since 1978. Further information: www.eQ-3.de , www.HomeMatic.com , www.homematic-ip.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005208/en/
Contact:
Press contact:
Sinje Salamon
eQ-3 AG
Marketing
Manager
+49 (491) 6008 - 626
sinje.salamon@eq-3.de
or
PR
agency:
Benjamin Kolthoff
P.U.N.K.T. Gesellschaft
für Public
Relations mbH
+49 (40) 85 37 60 - 29
bkolthoff@punkt-pr.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom